Clene Inc Raises over $28M in Oversubscribed Registered Direct Offering

Why It Matters

The progress of CNM‑Au8 moves Clene closer to delivering a disease‑modifying ALS therapy, addressing a high‑unmet‑need market and potentially unlocking substantial investor upside.

Key Takeaways

• Net loss fell to $26.2M, down from $39.4M.
• Cash on hand $5.2M after $28M capital raise.
• CNM‑Au8 reduced neurodegeneration biomarkers, no safety signals.
• FDA Type C meeting Q1 2026, NDA filing by June.
• Phase 3 ALS trial and MS studies planned for 2026.

Pulse Analysis

Clene Inc’s 2025 financial statement reflects a disciplined cost‑reduction strategy that narrowed its net loss to $26.2 million, a 33 percent improvement over the prior year. Revenue remained negligible at $200,000, underscoring the company’s focus on research rather than product sales. The balance sheet shows $5.2 million in cash after an oversubscribed $28 million registered direct offering, extending the cash runway into 2027. By trimming R&D and G&A expenses, Clene has positioned itself to fund its pivotal clinical programs without diluting shareholder value further.

The centerpiece of Clene’s pipeline, CNM‑Au8, is an investigational mitochondrial‑targeted therapy aimed at ALS and multiple sclerosis. Late‑stage biomarker analyses released in December 2025 demonstrated statistically significant reductions in neurodegeneration markers, while safety monitoring across more than 1,100 patient‑years revealed no major adverse events. These data have secured a Type C meeting with the FDA scheduled for early 2026, where the agency will review the biomarker and survival outcomes. Clene plans to submit an NDA under the accelerated approval pathway by June 2026, followed by a confirmatory Phase 3 ALS trial.

Success with CNM‑Au8 could reshape the ALS therapeutic landscape, where few disease‑modifying options exist and unmet clinical need remains high. An accelerated‑approval filing would place Clene among a limited group of biotech firms targeting mitochondrial health, potentially unlocking premium valuations and strategic partnerships. Moreover, the planned Phase 3 studies in multiple sclerosis broaden the addressable market and diversify risk. Investors are likely to weigh the company’s improved financial footing against the binary nature of late‑stage trials, making the upcoming regulatory milestones critical for future growth.

Deal Summary

Clene Inc announced it raised more than $28 million through an oversubscribed registered direct offering, boosting its cash balance to $5.2 million as of Dec. 31, 2025 and supporting operations into 2027. The fundraising was disclosed in the company's full‑year 2025 results.